Her previous roles at Juno Therapeutics, Celgene, and Lyell Immunopharma, and her current position as head of research at Tune Therapeutics, underscore her commitment to pioneering cancer treatments.

Celgene has today confirmed that it will acquire Juno Therapeutics for $9 billion, and says the move will make it a leader in cell immunotherapy. The price is a significant premium on the $5.5 bn ...

CAMBRIDGE, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the addition of Jerome ...

She has held research leadership roles at organizations including Juno Therapeutics, Celgene, and Lyell Immunopharma and is currently the head of research at Tune Therapeutics. She brings strong ...

Dr. Blackman co-founded Day One Biopharmaceuticals in 2018 with a vision to identify, acquire, and develop promising new treatments to address childhood cancers. Under Dr. Blackman’s leadership, Day ...

Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest funding rounds for a Seattle-area startup in recent years. Tune is using a ...

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial ...

Bestselling author Juno Dawson has entered the TARDIS for the upcoming Doctor Who. Dawson, who pens a Doctor Who spin-off podcast, is one of a number of new faces joining Russell T Davies ...